Please login to read the full article.
Scrip Regulatory Affairs
The future of product information in the EU
12 August 2011
Angelika Joos, Elisabeth Fournier-Qezari, Fiona Reekie, Merete Schmiegelow and Jan MacDonald
Please login to read the full article.
Not a subscriber ? Request a FREE Trial
Subscribe to Regulatory Affairs Pharma
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
- Brand vs generic: the battle rages over EU anti-counterfeit 'safety features'
- France votes for more regulatory transparency, tighter safety monitoring and tougher promotion controls
- EMA responds to criticism of reflection paper on non-clinical studies for generic nano-particle iron medicinal product applications
- EMA responds to criticism of reflection paper on non-clinical studies for generic nano-particle iron medicinal product applications
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
Other Informa Analysis
EDITORIALS
Regulatory Affairs Pharma Editorials
Other Informa Editorials
FEATURES
Regulatory Affairs Pharma Features
Other Informa Features
COMMENT
Regulatory Affairs Pharma Comment
Other Informa Comments
